Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | CFD | P00746 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PTGFR | P43088 | 1/20 | 0.34 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18055685 | 0.86 | PTGFR (0.43) | GPR119CFDNR1H3NR1H2PTGFR | |
| SCHEMBL13715039 | 0.86 | PTGFR (0.43) | GPR119CFDNR1H3NR1H2PTGFR | |
| SCHEMBL3386859 | 0.86 | PTGFR (0.39) | PTGFRHTRA1 | |
| SCHEMBL3385956 | 0.86 | PTGFR (0.39) | PTGFRHTRA1 | |
| SCHEMBL13004626 | 0.86 | PTGFR (0.39) | PTGFRHTRA1 | |
| SCHEMBL3382787 | 0.85 | CFD (0.40) | CFDPTGFR | |
| SCHEMBL13005178 | 0.84 | KDM4D (0.37) | GPR119CFDNR1H3NR1H2GHSR | |
| SCHEMBL13005236 | 0.83 | CFD (0.37) | CFDLMNAPTGFR | |
| SCHEMBL3382903 | 0.80 | RIPK1 (0.46) | CFDPTGFRHTRA1 | |
| SCHEMBL19118652 | 0.76 | PTGFR (0.40) | GPR119NR1H3NR1H2PTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415480-B2 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor | MERCK SERONO SA (CH) | 2013-04-09 | — | — | US | disclosed |
| US-8415480-B2 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor | MERCK SERONO SA (CH) | 2013-04-09 | — | — | US | disclosed |
| EP-1487442-B1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | MERCK SERONO SA (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20090215749-A9 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20090215749-A9 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20080255094-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2008-10-16 | — | — | US | disclosed |
| US-20080255094-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215749-A9 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | PTGER4, PTGER2, PTGER1 | GPR119 406/4885CFD 1099/4885NR1H3 1138/4885 |
| US-20080255094-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | PTGER4, PTGER2, PTGER1 | GPR119 406/4885CFD 1099/4885NR1H3 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.